中國心連心化肥(01866.HK)採納附屬公司股權激勵計劃 激勵對象認購河南心連心國際貿易新增註冊資本745萬元
格隆匯12月30日丨中國心連心化肥(01866.HK)發佈公吿,董事會已決議採納附屬公司股權激勵計劃的實施詳情,以認可激勵對象過去及現在對河南心連心國際貿易的貢獻,並激勵彼等在未來繼續作出貢獻。依據本計劃,河南心連心國際貿易的激勵股權將以認購河南心連心國際貿易新增股本的方式,通過合夥平台授予激勵對象。
激勵對象(通過合夥平台)出資總額約為人民幣745萬元,以認購河南心連心國際貿易新增註冊資本人民幣745萬元,即本計劃下增資事項完成後河南心連心國際貿易經擴大股本的約28.65%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.